Statement from the Alzheimer’s Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer’s Diagnosis

NEW YORK, May 16, 2025 /PRNewswire/ — Today, the FDA’s approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer’s disease. This is the first blood test authorized to aid in the diagnosis…